APOTEX HEALTH CORP. FILES FINAL PROSPECTUS AND ANNOUNCES PRICING OF UPSIZED INITIAL PUBLIC OFFERING

Executive Summary

• Apotex Health Corp. has priced its upsized initial public offering of 54,166,670 common shares at $24.00 per share, generating total gross proceeds of approximately $1.3 billion.
• The capital raise is structured as a primary treasury offering for the company (~$850M) and a secondary offering by existing shareholders (~$450M), with an over-allotment option for up to 8.125 million additional shares.
• Shares are scheduled to begin trading on the Toronto Stock Exchange under the symbol "APTX" on June 10, 2026, with closing expected around June 16, 2026.

Key Details

• Offering Price: $24.00 per Common Share
• Total Shares Offered: 54,166,670 Common Shares
• Total Gross Proceeds: $1,300,000,080
• Primary (Treasury) Offering: 35,416,666 shares, generating $849,999,984 in gross proceeds to Apotex
• Secondary Offering: 18,750,004 shares, generating $450,000,096 in gross proceeds to Selling Shareholders
• Over-Allotment Option: Underwriters granted an option to purchase up to 8,125,000 additional Common Shares at $24.00/share, exercisable at any time until 30 days after the closing date
• Underwriting Syndicate: Co-lead managers/joint global coordinators/joint lead bookrunners: RBC Capital Markets, TD Securities Inc., and Scotiabank; Joint bookrunners: BMO Capital Markets and Jefferies Securities, Inc.; Co-managers: CIBC Capital Markets, ATB Cormark Capital Markets, Desjardins Capital Markets, National Bank Capital Markets, MUFG, Raymond James, Bloom Burton Securities Inc., Canaccord Genuity Corp., Stifel, and Paradigm Capital Inc.
• Legal Counsel: Goodmans LLP (Canadian counsel to Apotex), Stikeman Elliott LLP (Canadian counsel to underwriters), Kirkland & Ellis LLP (US counsel to Apotex), Skadden, Arps, Slate, Meagher & Flom LLP (US counsel to underwriters)
• Closing Date: On or about June 16, 2026 (subject to customary closing conditions)
• Trading & Listing: Shares will begin trading on the TSX on an "if, as and when issued" basis on June 10, 2026 under the ticker symbol "APTX"; TSX listing is conditionally approved pending customary requirements
• Prospectus Filing: Final base PREP prospectus filed with Canadian securities regulatory authorities; supplemented prospectus containing pricing information will be available on SEDAR+ on or about June 10, 2026